Professor Terhi Piltonen explains why renaming PCOS to PMOS is a crucial step toward a multi-disciplinary and holistic approach to women's endocrine health.
- Polycystic Ovary Syndrome (PCOS) is being renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS).
- The change aims to address the condition as a whole-body metabolic and endocrine disorder rather than just an ovarian issue.
- The new nomenclature encourages involvement from dermatologists, psychologists, and nutritionists.
In a landmark move for women's healthcare, the Endocrine Society has announced the renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This shift, highlighted by Professor Terhi Piltonen, aims to rectify a long-standing clinical oversight where the condition was often reduced to its symptoms in the ovaries, ignoring its systemic nature.
The decision follows a global consensus published in The Lancet, led by Professor Helena J. Teede. The core argument was that the term 'PCOS' focused too narrowly on cysts and ovaries, potentially leading to underdiagnosis and inadequate treatment of the broader hormonal and metabolic implications that affect millions of women worldwide.
Why This Matters
BozokMedia analysis shows that this nomenclature shift marks a transition from organ-centric medicine to systemic health management. By adopting the term PMOS, the medical community acknowledges that the syndrome impacts mood, psychological stability, metabolic health, and skin integrity, necessitating a multi-disciplinary intervention.
"We are now thinking about it in a more holistic way; not only looking at the ovary, but also looking at how it affects the mood, the psychological profile, the metabolic profile and also the menstrual cycles." — Prof. Terhi Piltonen
Professor Piltonen, President of the AE-PCOS Society, emphasized that this change will bridge the gap between different medical specialties. While diagnosis has traditionally been the domain of OB-GYNs, the PMOS designation invites endocrinologists, dermatologists, and internal medicine specialists to take a leading role in patient care.
The transition also addresses the socioeconomic and evolutionary aspects of the condition. As modern diets shift toward high-energy, processed foods and societal stress levels rise, the prevalence of these metabolic imbalances increases. Professor Piltonen notes that current research funding often lags behind the actual prevalence of women's health issues compared to conditions like diabetes or erectile dysfunction.
| Feature | PCOS (Old Term) | PMOS (New Term) |
|---|---|---|
| Primary Focus | Ovaries and Cysts | Whole-body Endocrine & Metabolic System |
| Medical Scope | Obstetrics & Gynecology | Multi-disciplinary (Endo, Derm, Psych, Nutrition) |
| Treatment Goal | Symptom Management | Holistic Health & Quality of Life |
Frequently Asked Questions
1. Does the name change mean the disease is different?
No, the underlying biological condition remains the same, but the name better reflects the full spectrum of its effects on the body.
2. How will this affect patients currently undergoing treatment?
Patients will see a more comprehensive approach to their care, including better integration of mental health and metabolic management.
